We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Accuray (ARAY) Q3 Earnings Top Estimates, Gross Orders Rise
Read MoreHide Full Article
Accuray Incorporated (ARAY - Free Report) reported third-quarter fiscal 2019 adjusted loss of a penny per share, narrower than the Zacks Consensus Estimate of a loss of 4 cents. The company had reported a loss of 10 cents in the year-ago quarter.
Net revenues in the quarter totaled $103.2 million, missing the Zacks Consensus Estimate of $104 million. On a year-over-year basis, revenues climbed 3.4%.
Q3 Details
Product Revenues: Product revenues increased 7.6% year over year to $46.5 million in the reported quarter on strong demand for the Radixact system.
Service Revenues: Service revenues totaled $56.8 million, up 0.4% from the year-ago quarter on continued growth in installed base.
Accuray Incorporated Price, Consensus and EPS Surprise
Gross Order Update: Gross orders in the third quarter totaled $83.6 million, up 11.6% year over year. The upside was driven by strong demand for Radixact, CyberKnife and TomoTherapy platforms.CyberKnife contributed approximately 45% to total gross orders compared with 35% a year ago, primarily driven by strong demand in China.Radixact and TomoTherapy platform accounted for approximately 55% of third-quarter total gross orders.
However, gross orders in the United States, EMEA and Japan declined year over year in the quarter under review.
Margins
Gross profit in the fiscal third quarter totaled $40.5 million, up 11.6% on a year-over-year basis. Gross margin was 39.2%, highlighting an expansion of 290 basis points (bps) year over year.
Research and development expenses contracted 7.1% year over year to $12.9 million. Selling and marketing expenses declined 11.7% to $12.9 million. General and administrative expenses rose 1.9% to $11.8 million.
Third-quarter operating profit was $2.9 million against a loss of $3.8 million in the year-ago quarter. Operating margin was 2.8%.
Cash Position
The company exited third-quarter fiscal 2019 with total cash, cash equivalents, and short-term restricted cash of $64.6 million, flat sequentially.
2019 Guidance Reiterated
Accuray has kept its fiscal 2019 guidance unchanged.
The company expects product revenue growth between 4% and 8% and service revenues are projected to grow approximately 2%. This is expected to result in total revenues of $415-$425 million, indicating year-over-year growth of 3-5%.
Adjusted EBITDA is expected between $23 million to $29 million, suggesting 35-70% growth year over year.
Our Take
Accuray wrapped up the fiscal third quarter on a mixed note. While loss per share was narrower than estimates, revenues lagged the same.Solid demand for the company’s Radixact, CyberKnife and TomoTherapy platforms has continued to boost business. Expansion in gross margin also buoys optimism. We are also upbeat to note that this was the company’s fourth consecutive quarter of double-digit growth in gross orders, which was driven by continued strength in China. Accuray has also significantly operationalized its China joint venture agreement, which was signed in January. The deployment of the VOLO Optimizer software has also consolidated the company’s product development roadmap.
On the flip side, declining gross orders in United States, EMEA and Japan raise concern.
Zacks Rank and Key Picks
Accuray currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space are Bio-Rad Laboratories, Inc. (BIO - Free Report) , ICU Medical, Inc. (ICUI - Free Report) and Varian Medical Systems, Inc. .
Bio-Rad is scheduled to release first-quarter 2019 results on May 8. The Zacks Consensus Estimate for quarterly adjusted earnings per share (EPS) is pegged at $1.12 and for revenues at $548.8 million. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
ICU Medical is scheduled to release first-quarter 2019 results on May 9. The Zacks Consensus Estimate for the quarter’s adjusted EPS is $2.18 and for revenues, $321.1 million. The stock carries a Zacks Rank #2 (Buy).
Varian is slated to release first-quarter 2019 results on Apr 24. The Zacks Consensus Estimate for the quarterly adjusted EPS stands at $1.16 and for the top line, $779.01 million. The stock has a Zacks Rank of 2.
Will you retire a millionaire?
One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”
Image: Bigstock
Accuray (ARAY) Q3 Earnings Top Estimates, Gross Orders Rise
Accuray Incorporated (ARAY - Free Report) reported third-quarter fiscal 2019 adjusted loss of a penny per share, narrower than the Zacks Consensus Estimate of a loss of 4 cents. The company had reported a loss of 10 cents in the year-ago quarter.
Net revenues in the quarter totaled $103.2 million, missing the Zacks Consensus Estimate of $104 million. On a year-over-year basis, revenues climbed 3.4%.
Q3 Details
Product Revenues: Product revenues increased 7.6% year over year to $46.5 million in the reported quarter on strong demand for the Radixact system.
Service Revenues: Service revenues totaled $56.8 million, up 0.4% from the year-ago quarter on continued growth in installed base.
Accuray Incorporated Price, Consensus and EPS Surprise
Accuray Incorporated Price, Consensus and EPS Surprise | Accuray Incorporated Quote
Gross Order Update: Gross orders in the third quarter totaled $83.6 million, up 11.6% year over year. The upside was driven by strong demand for Radixact, CyberKnife and TomoTherapy platforms.CyberKnife contributed approximately 45% to total gross orders compared with 35% a year ago, primarily driven by strong demand in China.Radixact and TomoTherapy platform accounted for approximately 55% of third-quarter total gross orders.
However, gross orders in the United States, EMEA and Japan declined year over year in the quarter under review.
Margins
Gross profit in the fiscal third quarter totaled $40.5 million, up 11.6% on a year-over-year basis. Gross margin was 39.2%, highlighting an expansion of 290 basis points (bps) year over year.
Research and development expenses contracted 7.1% year over year to $12.9 million. Selling and marketing expenses declined 11.7% to $12.9 million. General and administrative expenses rose 1.9% to $11.8 million.
Third-quarter operating profit was $2.9 million against a loss of $3.8 million in the year-ago quarter. Operating margin was 2.8%.
Cash Position
The company exited third-quarter fiscal 2019 with total cash, cash equivalents, and short-term restricted cash of $64.6 million, flat sequentially.
2019 Guidance Reiterated
Accuray has kept its fiscal 2019 guidance unchanged.
The company expects product revenue growth between 4% and 8% and service revenues are projected to grow approximately 2%. This is expected to result in total revenues of $415-$425 million, indicating year-over-year growth of 3-5%.
Adjusted EBITDA is expected between $23 million to $29 million, suggesting 35-70% growth year over year.
Our Take
Accuray wrapped up the fiscal third quarter on a mixed note. While loss per share was narrower than estimates, revenues lagged the same.Solid demand for the company’s Radixact, CyberKnife and TomoTherapy platforms has continued to boost business. Expansion in gross margin also buoys optimism. We are also upbeat to note that this was the company’s fourth consecutive quarter of double-digit growth in gross orders, which was driven by continued strength in China. Accuray has also significantly operationalized its China joint venture agreement, which was signed in January. The deployment of the VOLO Optimizer software has also consolidated the company’s product development roadmap.
On the flip side, declining gross orders in United States, EMEA and Japan raise concern.
Zacks Rank and Key Picks
Accuray currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space are Bio-Rad Laboratories, Inc. (BIO - Free Report) , ICU Medical, Inc. (ICUI - Free Report) and Varian Medical Systems, Inc. .
Bio-Rad is scheduled to release first-quarter 2019 results on May 8. The Zacks Consensus Estimate for quarterly adjusted earnings per share (EPS) is pegged at $1.12 and for revenues at $548.8 million. The stock sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
ICU Medical is scheduled to release first-quarter 2019 results on May 9. The Zacks Consensus Estimate for the quarter’s adjusted EPS is $2.18 and for revenues, $321.1 million. The stock carries a Zacks Rank #2 (Buy).
Varian is slated to release first-quarter 2019 results on Apr 24. The Zacks Consensus Estimate for the quarterly adjusted EPS stands at $1.16 and for the top line, $779.01 million. The stock has a Zacks Rank of 2.
Will you retire a millionaire?
One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”
Click to get it free >>